Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Post-Traumatic Stress Disorder (PTSD) Overview 8
Therapeutics Development 9
An Overview of Pipeline Products for Post-Traumatic Stress Disorder (PTSD) 9
Post-Traumatic Stress Disorder (PTSD) Therapeutics under Development by Companies 11
Post-Traumatic Stress Disorder (PTSD) Therapeutics under Investigation by Universities/Institutes 12
Late Stage Products 14
Comparative Analysis 14
Mid Clinical Stage Products 15
Comparative Analysis 15
Early Clinical Stage Products 16
Comparative Analysis 16
Post-Traumatic Stress Disorder (PTSD) Therapeutics – Products under Development by Companies 17
Post-Traumatic Stress Disorder (PTSD) Therapeutics – Products under Investigation by Universities/Institutes 18
Companies Involved in Post-Traumatic Stress Disorder (PTSD) Therapeutics Development 19
Nanotherapeutics, Inc. 19
Biotie Therapies Corp. 20
Azevan Pharmaceuticals, Inc. 21
Marinus Pharmaceuticals, Inc. 22
Post-Traumatic Stress Disorder (PTSD) – Therapeutics Assessment 23
Assessment by Monotherapy Products 23
Assessment by Combination Products 24
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Drug Profiles 29
Nepicastat - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
PRX-3140 - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
SRX251 - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
SRX246 - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Ketamine - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
GR205171 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Aprepitant - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Ganaxolone - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Paroxetine-CR - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
3,4-Methylenedioxymethamphetamine - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Yohimbine - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Neuropeptide Y - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Guanfacine - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Mifepristone - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
D-Cycloserine - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Propranolol - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Carvedilol - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
Propranolol - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Prazosin - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
Methylphenidate Hydrochloride - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
D-Cycloserine + Prolonged Imaginal Exposure - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Post-Traumatic Stress Disorder (PTSD) Therapeutics – Drug Profile Updates 56
Post-Traumatic Stress Disorder (PTSD) Therapeutics – Discontinued Products 59
Post-Traumatic Stress Disorder (PTSD) Therapeutics - Dormant Products 60
Post-Traumatic Stress Disorder (PTSD) – Product Development Milestones 61
Featured News & Press Releases 61
Jun 20, 2011: Neuralstem On Schedule To Complete Phase Ia Trial Of NSI-189 In Major Depression 61
Apr 21, 2011: Marinus Announces Commencement Of Phase II Trial Of Ganaxolone In Posttraumatic Stress Disorder 61
Apr 07, 2011: Marinus Receives US Patent For Ganaxolone 62
Jul 24, 2008: US Department Of Defense To Fund Phase II Trial Of Synosia Therapeutics Nepicastat For Post-Traumatic Stress Disorder 62
Apr 28, 2005: SkyePharma and GlaxoSmithKline reach agreement on payment of royalties for Paxil CR. 63
Feb 25, 2004: Paxil CR receives US FDA approval for additional indication. 63
Feb 24, 2004: US FDA approves intermittent dosing of Paxil CR for the treatment of premenstrual dysphoric disorder (pmdd); new two-week regimens offer flexibility and convenience in alleviating emotional and physical symptoms of PMDD. 64
Jan 12, 2004: SkyePharma Welcomes Canadian Approval of Paxil CR. 64
Oct 20, 2003: SkyePharma welcomes US FDA approval of additional indication for Paxil CR; Paxil CR becomes the first and only Controlled-Release SSRI antidepressant approved for social anxiety disorder. 64
Dec 07, 1999: Pfizer's Zoloft Approved By US FDA For the Treatment of Posttraumatic Stress Disorder 64
Appendix 65
Methodology 65
Coverage 65
Secondary Research 65
Primary Research 65
Expert Panel Validation 65
Contact Us 66
Disclaimer 66
List of Tables
Number of Products Under Development for Post-Traumatic Stress Disorder (PTSD), H1 2012 9
Products under Development for Post-Traumatic Stress Disorder (PTSD) – Comparative Analysis, H1 2012 10
Number of Products under Development by Companies, H1 2012 11
Number of Products under Investigation by Universities/Institutes, H1 2012 13
Comparative Analysis by Late Stage Development, H1 2012 14
Comparative Analysis by Mid Clinical Stage Development, H1 2012 15
Comparative Analysis by Early Clinical Stage Development, H1 2012 16
Products under Development by Companies, H1 2012 17
Products under Investigation by Universities/Institutes, H1 2012 18
Nanotherapeutics, Inc., H1 2012 19
Biotie Therapies Corp., H1 2012 20
Azevan Pharmaceuticals, Inc., H1 2012 21
Marinus Pharmaceuticals, Inc., H1 2012 22
Assessment by Monotherapy Products, H1 2012 23
Assessment by Combination Products, H1 2012 24
Assessment by Stage and Route of Administration, H1 2012 26
Assessment by Stage and Molecule Type, H1 2012 28
Post-Traumatic Stress Disorder (PTSD) Therapeutics – Drug Profile Updates 56
Post-Traumatic Stress Disorder (PTSD) Therapeutics – Discontinued Products 59
Post-Traumatic Stress Disorder (PTSD) Therapeutics – Dormant Products 60
List of Figures
Number of Products under Development for Post-Traumatic Stress Disorder (PTSD), H1 2012 9
Products under Development for Post-Traumatic Stress Disorder (PTSD) – Comparative Analysis, H1 2012 10
Products under Development by Companies, H1 2012 11
Products under Investigation by Universities/Institutes, H1 2012 12
Late Stage Products, H1 2012 14
Mid Clinical Stage Products, H1 2012 15
Early Clinical Stage Products, H1 2012 16
Assessment by Monotherapy Products, H1 2012 23
Assessment by Combination Products, H1 2012 24
Assessment by Route of Administration, H1 2012 25
Assessment by Stage and Route of Administration, H1 2012 26
Assessment by Molecule Type, H1 2012 27
Assessment by Stage and Molecule Type, H1 2012 28